Rescue of p53 function by MDM2 antagonist, Nutlin-3, enhances the apoptotic synergism between MEK1 inhibitor and arsenic trioxide

被引：0
|
作者：
Lunghi, P.
Mazzera, L.
Rizzoli, V.
Bonati, A.
机构：
[1] Univ Parma, Dept Clin Sci, I-43100 Parma, Italy
[2] Univ Parma, Hematol Unit, I-43100 Parma, Italy
[3] Univ Parma, Dept Internal Med, I-43100 Parma, Italy
来源：
EXPERIMENTAL HEMATOLOGY | 2007年 / 35卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [41] MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway
    Zauli, Giorgio
    Rimondi, Erika
    Corallini, Federica
    Fadda, Roberto
    Capitani, Silvano
    Secchiero, Paola
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (10) : 1621 - 1630
  • [42] 1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53
    Thompson, Thelma
    Andreeff, Michael
    Studzinski, George P.
    Vassilev, Lyubomir T.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) : 1158 - 1168
  • [43] Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
    U Kaindl
    M Morak
    C Portsmouth
    A Mecklenbräuker
    M Kauer
    M Zeginigg
    A Attarbaschi
    O A Haas
    R Panzer-Grümayer
    [J]. Leukemia, 2014, 28 : 600 - 608
  • [44] Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
    Kaindl, U.
    Morak, M.
    Portsmouth, C.
    Mecklenbraeuker, A.
    Kauer, M.
    Zeginigg, M.
    Attarbaschi, A.
    Haas, O. A.
    Panzer-Gruemayer, R.
    [J]. LEUKEMIA, 2014, 28 (03) : 600 - 608
  • [45] Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
    Chithra D. Palani
    James F. Beck
    Jürgen Sonnemann
    [J]. Investigational New Drugs, 2012, 30 : 25 - 36
  • [46] The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
    Seipel, Katja
    Marques, Miguel A. T.
    Sidler, Corinne
    Mueller, Beatrice U.
    Pabst, Thomas
    [J]. CANCERS, 2018, 10 (06)
  • [47] Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
    Palani, Chithra D.
    Beck, James F.
    Sonnemann, Juergen
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 25 - 36
  • [48] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    SHEN HongChang
    [J]. Science Bulletin, 2012, (09) : 1007 - 1012
  • [49] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    Shen HongChang
    Dong Wei
    Gao DongWei
    Wang GuangHui
    Ma GuoYuan
    Liu Qi
    Du JiaJun
    [J]. CHINESE SCIENCE BULLETIN, 2012, 57 (09): : 1007 - 1012
  • [50] Nutlin-3, a MDM2 antagonist, induces Erk1/2 activation in U2OS cells
    Lee, Sun-Young
    Ko, Kyoung-Won
    Choe, Yun-Jung
    Jeong, Seong-Whan
    Kim, Ho-Shik
    [J]. FASEB JOURNAL, 2010, 24
12345